• 1
    Sander JWAS, New drugs for epilepsy. Curr Opin Neurol 1998;11:1418.
  • 2
    Reife RA, Pledger GW, Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double blind, placebo controlled trials, Epilepsia 1997;38(suppl l):S313.
  • 3
    Marson AG, Kadir ZA, Chadwick DW, New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313:116974.
  • 4
    Mignot G., Drug trials in epilepsy. BMJ 1996;313:1158.
  • 5
    Brodie MJ, Richens A, Yuen AW, Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK lamotrigine/carbamazepine monotherapy trial group. Lancet 1995;345:4769.
  • 6
    Kellet MW, Smith DF, Stockton PA, Chadwick DW, Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66:75963.
  • 7
    Wong ICK, New antiepileptic drugs: study suggests that a quarter of patients will still be taking the new drugs after six years. BMJ 1997;314:6034.
  • 8
    Kaplan EL, Non-parametric estimation from incomplete observations. Am Stat Assoc J 1958;53:45781.
  • 9
    Cox DR, Regression models and life tables. J R Stat Soc 1972;34:187202.
  • 10
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:38999.
  • 11
    World Health Organization. Guidelines for ATC classification and DDD assignment. WHO, 1996.
  • 12
    Smith D, Baker G, Davies G, Dewey M, Chadwick DW, Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:31222.
  • 13
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:3217.